Who is sponsoring NCT00000872?

NCT00000872 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00000872 study?

NCT00000872 studies HIV Infections.

What drugs are being tested in NCT00000872?

Interventions: Abacavir sulfate, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine, Zidovudine.

What is the status of NCT00000872?

NCT00000872 is currently COMPLETED.

Last reviewed 2021-10-27 · How we verify

Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children

NCT00000872 Phase 2 COMPLETED

This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 2
Status	COMPLETED
Enrolment	55
Completion	2005-01

Conditions

HIV Infections

Interventions

Abacavir sulfate
Nelfinavir mesylate
Nevirapine
Lamivudine
Stavudine
Zidovudine

Primary outcomes

Antiretroviral activity of ZDV/3TC/NVP — Throughout study
Durability of viral suppression — Throughout study
Immune competence and HIV-1 specific immune respones with prolonged viral suppression beyond 104 weeks — Throughout study
Antiretroviral activity of ZDV/3TC/NVP/1592U89 regimen — Throughout study
Antiretroviral activity of d4T/3TC/NVP/NFV regimen — Throughout study
Tolerance and pharmacokinetic profile of NFV — Throughout study

Countries

United States